Global Procalcitonin

Procalcitonin Comprehensive Study by Type (Polyclonal Procalcitonin Antibody, Monoclonal Procalcitonin Antibody), Application (Diagnose Sepis, Diagnose Kidney Infections, Monitor the Effectivenees of Antibiotics Therapy), End use (Medical Industry, Scientific Research) Players and Region - Global Market Outlook to 2030

Procalcitonin Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 6.2%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Procalcitonin Market Scope
Procalcitonin is produced by parfollicular cells of thyroid and calcitonin is produced by the C‐cells of the thyroid medulla and neuroendocrine cells in the lungs and intestine in response to tissue injury. Also, it contains 116 amino acids. It is below the limit of detection of clinical assays in healthy individuals. According to CDC nearly half a million Americans suffered from Clostridium difficile infections in 2015. The procalcitonin test can be used to detect infections such as sepsis and Clostridium difficile.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledThermo Fisher (United States), Roche Diagnostics (Switzerland), BioMerieux (France), HyTest (Finland), BBI Solutions (Brazil), ProSpec (United Kingdom), CPN (Thailand), Kewpie (Japan), Shiseido (Japan) and Novozymes (Denmark)
CAGR6.2%


The rising number of players expected to enter the global market is predicted to enhance the competition level as well as encourage the growth of the overall market shortly. Players are anticipated to focus on the development of new compounds, which is likely to encourage the growth of the global market throughout the forecast period. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Procalcitonin market throughout the predicted period.

Thermo Fisher (United States), Roche Diagnostics (Switzerland), BioMerieux (France), HyTest (Finland), BBI Solutions (Brazil), ProSpec (United Kingdom), CPN (Thailand), Kewpie (Japan), Shiseido (Japan) and Novozymes (Denmark) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Bloomage BioTechnology (China), Shandong Galaxy Bio-Tech (China), Shandong Focuschem Biotech Co., Ltd. (China), Shandong Topscience Biotech (China) and QuFu GuangLong Biochem (China).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Procalcitonin market by Type , by Application (Diagnose Sepis, Diagnose Kidney Infections and Monitor the Effectivenees of Antibiotics Therapy) and Region with country level break-up.

On the basis of geography, the market of Procalcitonin has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2023.

Market Leaders and their expansionary development strategies

In July 2021, DiaSys Diagnostics India Pvt. Ltd. launched a new reagent called Procalcitonin FS, which is a fluid-stable, particle-enhanced immunoturbidimetry assay. This product provides a convenient workflow on clinical chemistry analyzers.


Influencing Trend:
Technological Advancements are Being Done

Market Growth Drivers:
Rising Bacterial Infections and Diseases Among the People and Usage in Diagnosis of Various Infections Such as Kidney

Challenges:
Lack of Awareness of Procalcitonin and Low Degree of Specificity in Detection of Sepis as the Procalcitonin can be Raised by Other Viral Infections

Restraints:
High Costs Associated with the Procalcitonin Test and High Competition due to the Availability of Major Players

Opportunities:
Increasing Demand in Developing Countries

Key Target Audience
Manufacturers, Raw Material Suppliers, Distributors and Traders, Research Organizations, Government Agencies and Organizations

Report Objectives / Segmentation Covered

By Type
  • Polyclonal Procalcitonin Antibody
  • Monoclonal Procalcitonin Antibody
By Application
  • Diagnose Sepis
  • Diagnose Kidney Infections
  • Monitor the Effectivenees of Antibiotics Therapy
By End use
  • Medical Industry
  • Scientific Research

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Bacterial Infections and Diseases Among the People
      • 3.2.2. Usage in Diagnosis of Various Infections Such as Kidney
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness of Procalcitonin
      • 3.3.2. Low Degree of Specificity in Detection of Sepis as the Procalcitonin can be Raised by Other Viral Infections
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements are Being Done
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Procalcitonin, by Type, Application, End use and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Procalcitonin (Value)
      • 5.2.1. Global Procalcitonin by: Type (Value)
        • 5.2.1.1. Polyclonal Procalcitonin Antibody
        • 5.2.1.2. Monoclonal Procalcitonin Antibody
      • 5.2.2. Global Procalcitonin by: Application (Value)
        • 5.2.2.1. Diagnose Sepis
        • 5.2.2.2. Diagnose Kidney Infections
        • 5.2.2.3. Monitor the Effectivenees of Antibiotics Therapy
      • 5.2.3. Global Procalcitonin by: End use (Value)
        • 5.2.3.1. Medical Industry
        • 5.2.3.2. Scientific Research
      • 5.2.4. Global Procalcitonin Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Procalcitonin (Price)
      • 5.3.1. Global Procalcitonin by: Type (Price)
  • 6. Procalcitonin: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Thermo Fisher (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Roche Diagnostics (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. BioMerieux (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. HyTest (Finland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. BBI Solutions (Brazil)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. ProSpec (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. CPN (Thailand)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Kewpie (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Shiseido (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Novozymes (Denmark)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Procalcitonin Sale, by Type, Application, End use and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Procalcitonin (Value)
      • 7.2.1. Global Procalcitonin by: Type (Value)
        • 7.2.1.1. Polyclonal Procalcitonin Antibody
        • 7.2.1.2. Monoclonal Procalcitonin Antibody
      • 7.2.2. Global Procalcitonin by: Application (Value)
        • 7.2.2.1. Diagnose Sepis
        • 7.2.2.2. Diagnose Kidney Infections
        • 7.2.2.3. Monitor the Effectivenees of Antibiotics Therapy
      • 7.2.3. Global Procalcitonin by: End use (Value)
        • 7.2.3.1. Medical Industry
        • 7.2.3.2. Scientific Research
      • 7.2.4. Global Procalcitonin Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Procalcitonin (Price)
      • 7.3.1. Global Procalcitonin by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Procalcitonin: by Type(USD Million)
  • Table 2. Procalcitonin Polyclonal Procalcitonin Antibody , by Region USD Million (2018-2023)
  • Table 3. Procalcitonin Monoclonal Procalcitonin Antibody , by Region USD Million (2018-2023)
  • Table 4. Procalcitonin: by Application(USD Million)
  • Table 5. Procalcitonin Diagnose Sepis , by Region USD Million (2018-2023)
  • Table 6. Procalcitonin Diagnose Kidney Infections , by Region USD Million (2018-2023)
  • Table 7. Procalcitonin Monitor the Effectivenees of Antibiotics Therapy , by Region USD Million (2018-2023)
  • Table 8. Procalcitonin: by End use(USD Million)
  • Table 9. Procalcitonin Medical Industry , by Region USD Million (2018-2023)
  • Table 10. Procalcitonin Scientific Research , by Region USD Million (2018-2023)
  • Table 11. South America Procalcitonin, by Country USD Million (2018-2023)
  • Table 12. South America Procalcitonin, by Type USD Million (2018-2023)
  • Table 13. South America Procalcitonin, by Application USD Million (2018-2023)
  • Table 14. South America Procalcitonin, by End use USD Million (2018-2023)
  • Table 15. Brazil Procalcitonin, by Type USD Million (2018-2023)
  • Table 16. Brazil Procalcitonin, by Application USD Million (2018-2023)
  • Table 17. Brazil Procalcitonin, by End use USD Million (2018-2023)
  • Table 18. Argentina Procalcitonin, by Type USD Million (2018-2023)
  • Table 19. Argentina Procalcitonin, by Application USD Million (2018-2023)
  • Table 20. Argentina Procalcitonin, by End use USD Million (2018-2023)
  • Table 21. Rest of South America Procalcitonin, by Type USD Million (2018-2023)
  • Table 22. Rest of South America Procalcitonin, by Application USD Million (2018-2023)
  • Table 23. Rest of South America Procalcitonin, by End use USD Million (2018-2023)
  • Table 24. Asia Pacific Procalcitonin, by Country USD Million (2018-2023)
  • Table 25. Asia Pacific Procalcitonin, by Type USD Million (2018-2023)
  • Table 26. Asia Pacific Procalcitonin, by Application USD Million (2018-2023)
  • Table 27. Asia Pacific Procalcitonin, by End use USD Million (2018-2023)
  • Table 28. China Procalcitonin, by Type USD Million (2018-2023)
  • Table 29. China Procalcitonin, by Application USD Million (2018-2023)
  • Table 30. China Procalcitonin, by End use USD Million (2018-2023)
  • Table 31. Japan Procalcitonin, by Type USD Million (2018-2023)
  • Table 32. Japan Procalcitonin, by Application USD Million (2018-2023)
  • Table 33. Japan Procalcitonin, by End use USD Million (2018-2023)
  • Table 34. India Procalcitonin, by Type USD Million (2018-2023)
  • Table 35. India Procalcitonin, by Application USD Million (2018-2023)
  • Table 36. India Procalcitonin, by End use USD Million (2018-2023)
  • Table 37. South Korea Procalcitonin, by Type USD Million (2018-2023)
  • Table 38. South Korea Procalcitonin, by Application USD Million (2018-2023)
  • Table 39. South Korea Procalcitonin, by End use USD Million (2018-2023)
  • Table 40. Taiwan Procalcitonin, by Type USD Million (2018-2023)
  • Table 41. Taiwan Procalcitonin, by Application USD Million (2018-2023)
  • Table 42. Taiwan Procalcitonin, by End use USD Million (2018-2023)
  • Table 43. Australia Procalcitonin, by Type USD Million (2018-2023)
  • Table 44. Australia Procalcitonin, by Application USD Million (2018-2023)
  • Table 45. Australia Procalcitonin, by End use USD Million (2018-2023)
  • Table 46. Rest of Asia-Pacific Procalcitonin, by Type USD Million (2018-2023)
  • Table 47. Rest of Asia-Pacific Procalcitonin, by Application USD Million (2018-2023)
  • Table 48. Rest of Asia-Pacific Procalcitonin, by End use USD Million (2018-2023)
  • Table 49. Europe Procalcitonin, by Country USD Million (2018-2023)
  • Table 50. Europe Procalcitonin, by Type USD Million (2018-2023)
  • Table 51. Europe Procalcitonin, by Application USD Million (2018-2023)
  • Table 52. Europe Procalcitonin, by End use USD Million (2018-2023)
  • Table 53. Germany Procalcitonin, by Type USD Million (2018-2023)
  • Table 54. Germany Procalcitonin, by Application USD Million (2018-2023)
  • Table 55. Germany Procalcitonin, by End use USD Million (2018-2023)
  • Table 56. France Procalcitonin, by Type USD Million (2018-2023)
  • Table 57. France Procalcitonin, by Application USD Million (2018-2023)
  • Table 58. France Procalcitonin, by End use USD Million (2018-2023)
  • Table 59. Italy Procalcitonin, by Type USD Million (2018-2023)
  • Table 60. Italy Procalcitonin, by Application USD Million (2018-2023)
  • Table 61. Italy Procalcitonin, by End use USD Million (2018-2023)
  • Table 62. United Kingdom Procalcitonin, by Type USD Million (2018-2023)
  • Table 63. United Kingdom Procalcitonin, by Application USD Million (2018-2023)
  • Table 64. United Kingdom Procalcitonin, by End use USD Million (2018-2023)
  • Table 65. Netherlands Procalcitonin, by Type USD Million (2018-2023)
  • Table 66. Netherlands Procalcitonin, by Application USD Million (2018-2023)
  • Table 67. Netherlands Procalcitonin, by End use USD Million (2018-2023)
  • Table 68. Rest of Europe Procalcitonin, by Type USD Million (2018-2023)
  • Table 69. Rest of Europe Procalcitonin, by Application USD Million (2018-2023)
  • Table 70. Rest of Europe Procalcitonin, by End use USD Million (2018-2023)
  • Table 71. MEA Procalcitonin, by Country USD Million (2018-2023)
  • Table 72. MEA Procalcitonin, by Type USD Million (2018-2023)
  • Table 73. MEA Procalcitonin, by Application USD Million (2018-2023)
  • Table 74. MEA Procalcitonin, by End use USD Million (2018-2023)
  • Table 75. Middle East Procalcitonin, by Type USD Million (2018-2023)
  • Table 76. Middle East Procalcitonin, by Application USD Million (2018-2023)
  • Table 77. Middle East Procalcitonin, by End use USD Million (2018-2023)
  • Table 78. Africa Procalcitonin, by Type USD Million (2018-2023)
  • Table 79. Africa Procalcitonin, by Application USD Million (2018-2023)
  • Table 80. Africa Procalcitonin, by End use USD Million (2018-2023)
  • Table 81. North America Procalcitonin, by Country USD Million (2018-2023)
  • Table 82. North America Procalcitonin, by Type USD Million (2018-2023)
  • Table 83. North America Procalcitonin, by Application USD Million (2018-2023)
  • Table 84. North America Procalcitonin, by End use USD Million (2018-2023)
  • Table 85. United States Procalcitonin, by Type USD Million (2018-2023)
  • Table 86. United States Procalcitonin, by Application USD Million (2018-2023)
  • Table 87. United States Procalcitonin, by End use USD Million (2018-2023)
  • Table 88. Canada Procalcitonin, by Type USD Million (2018-2023)
  • Table 89. Canada Procalcitonin, by Application USD Million (2018-2023)
  • Table 90. Canada Procalcitonin, by End use USD Million (2018-2023)
  • Table 91. Mexico Procalcitonin, by Type USD Million (2018-2023)
  • Table 92. Mexico Procalcitonin, by Application USD Million (2018-2023)
  • Table 93. Mexico Procalcitonin, by End use USD Million (2018-2023)
  • Table 94. Procalcitonin: by Type(USD/Units)
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Procalcitonin: by Type(USD Million)
  • Table 106. Procalcitonin Polyclonal Procalcitonin Antibody , by Region USD Million (2025-2030)
  • Table 107. Procalcitonin Monoclonal Procalcitonin Antibody , by Region USD Million (2025-2030)
  • Table 108. Procalcitonin: by Application(USD Million)
  • Table 109. Procalcitonin Diagnose Sepis , by Region USD Million (2025-2030)
  • Table 110. Procalcitonin Diagnose Kidney Infections , by Region USD Million (2025-2030)
  • Table 111. Procalcitonin Monitor the Effectivenees of Antibiotics Therapy , by Region USD Million (2025-2030)
  • Table 112. Procalcitonin: by End use(USD Million)
  • Table 113. Procalcitonin Medical Industry , by Region USD Million (2025-2030)
  • Table 114. Procalcitonin Scientific Research , by Region USD Million (2025-2030)
  • Table 115. South America Procalcitonin, by Country USD Million (2025-2030)
  • Table 116. South America Procalcitonin, by Type USD Million (2025-2030)
  • Table 117. South America Procalcitonin, by Application USD Million (2025-2030)
  • Table 118. South America Procalcitonin, by End use USD Million (2025-2030)
  • Table 119. Brazil Procalcitonin, by Type USD Million (2025-2030)
  • Table 120. Brazil Procalcitonin, by Application USD Million (2025-2030)
  • Table 121. Brazil Procalcitonin, by End use USD Million (2025-2030)
  • Table 122. Argentina Procalcitonin, by Type USD Million (2025-2030)
  • Table 123. Argentina Procalcitonin, by Application USD Million (2025-2030)
  • Table 124. Argentina Procalcitonin, by End use USD Million (2025-2030)
  • Table 125. Rest of South America Procalcitonin, by Type USD Million (2025-2030)
  • Table 126. Rest of South America Procalcitonin, by Application USD Million (2025-2030)
  • Table 127. Rest of South America Procalcitonin, by End use USD Million (2025-2030)
  • Table 128. Asia Pacific Procalcitonin, by Country USD Million (2025-2030)
  • Table 129. Asia Pacific Procalcitonin, by Type USD Million (2025-2030)
  • Table 130. Asia Pacific Procalcitonin, by Application USD Million (2025-2030)
  • Table 131. Asia Pacific Procalcitonin, by End use USD Million (2025-2030)
  • Table 132. China Procalcitonin, by Type USD Million (2025-2030)
  • Table 133. China Procalcitonin, by Application USD Million (2025-2030)
  • Table 134. China Procalcitonin, by End use USD Million (2025-2030)
  • Table 135. Japan Procalcitonin, by Type USD Million (2025-2030)
  • Table 136. Japan Procalcitonin, by Application USD Million (2025-2030)
  • Table 137. Japan Procalcitonin, by End use USD Million (2025-2030)
  • Table 138. India Procalcitonin, by Type USD Million (2025-2030)
  • Table 139. India Procalcitonin, by Application USD Million (2025-2030)
  • Table 140. India Procalcitonin, by End use USD Million (2025-2030)
  • Table 141. South Korea Procalcitonin, by Type USD Million (2025-2030)
  • Table 142. South Korea Procalcitonin, by Application USD Million (2025-2030)
  • Table 143. South Korea Procalcitonin, by End use USD Million (2025-2030)
  • Table 144. Taiwan Procalcitonin, by Type USD Million (2025-2030)
  • Table 145. Taiwan Procalcitonin, by Application USD Million (2025-2030)
  • Table 146. Taiwan Procalcitonin, by End use USD Million (2025-2030)
  • Table 147. Australia Procalcitonin, by Type USD Million (2025-2030)
  • Table 148. Australia Procalcitonin, by Application USD Million (2025-2030)
  • Table 149. Australia Procalcitonin, by End use USD Million (2025-2030)
  • Table 150. Rest of Asia-Pacific Procalcitonin, by Type USD Million (2025-2030)
  • Table 151. Rest of Asia-Pacific Procalcitonin, by Application USD Million (2025-2030)
  • Table 152. Rest of Asia-Pacific Procalcitonin, by End use USD Million (2025-2030)
  • Table 153. Europe Procalcitonin, by Country USD Million (2025-2030)
  • Table 154. Europe Procalcitonin, by Type USD Million (2025-2030)
  • Table 155. Europe Procalcitonin, by Application USD Million (2025-2030)
  • Table 156. Europe Procalcitonin, by End use USD Million (2025-2030)
  • Table 157. Germany Procalcitonin, by Type USD Million (2025-2030)
  • Table 158. Germany Procalcitonin, by Application USD Million (2025-2030)
  • Table 159. Germany Procalcitonin, by End use USD Million (2025-2030)
  • Table 160. France Procalcitonin, by Type USD Million (2025-2030)
  • Table 161. France Procalcitonin, by Application USD Million (2025-2030)
  • Table 162. France Procalcitonin, by End use USD Million (2025-2030)
  • Table 163. Italy Procalcitonin, by Type USD Million (2025-2030)
  • Table 164. Italy Procalcitonin, by Application USD Million (2025-2030)
  • Table 165. Italy Procalcitonin, by End use USD Million (2025-2030)
  • Table 166. United Kingdom Procalcitonin, by Type USD Million (2025-2030)
  • Table 167. United Kingdom Procalcitonin, by Application USD Million (2025-2030)
  • Table 168. United Kingdom Procalcitonin, by End use USD Million (2025-2030)
  • Table 169. Netherlands Procalcitonin, by Type USD Million (2025-2030)
  • Table 170. Netherlands Procalcitonin, by Application USD Million (2025-2030)
  • Table 171. Netherlands Procalcitonin, by End use USD Million (2025-2030)
  • Table 172. Rest of Europe Procalcitonin, by Type USD Million (2025-2030)
  • Table 173. Rest of Europe Procalcitonin, by Application USD Million (2025-2030)
  • Table 174. Rest of Europe Procalcitonin, by End use USD Million (2025-2030)
  • Table 175. MEA Procalcitonin, by Country USD Million (2025-2030)
  • Table 176. MEA Procalcitonin, by Type USD Million (2025-2030)
  • Table 177. MEA Procalcitonin, by Application USD Million (2025-2030)
  • Table 178. MEA Procalcitonin, by End use USD Million (2025-2030)
  • Table 179. Middle East Procalcitonin, by Type USD Million (2025-2030)
  • Table 180. Middle East Procalcitonin, by Application USD Million (2025-2030)
  • Table 181. Middle East Procalcitonin, by End use USD Million (2025-2030)
  • Table 182. Africa Procalcitonin, by Type USD Million (2025-2030)
  • Table 183. Africa Procalcitonin, by Application USD Million (2025-2030)
  • Table 184. Africa Procalcitonin, by End use USD Million (2025-2030)
  • Table 185. North America Procalcitonin, by Country USD Million (2025-2030)
  • Table 186. North America Procalcitonin, by Type USD Million (2025-2030)
  • Table 187. North America Procalcitonin, by Application USD Million (2025-2030)
  • Table 188. North America Procalcitonin, by End use USD Million (2025-2030)
  • Table 189. United States Procalcitonin, by Type USD Million (2025-2030)
  • Table 190. United States Procalcitonin, by Application USD Million (2025-2030)
  • Table 191. United States Procalcitonin, by End use USD Million (2025-2030)
  • Table 192. Canada Procalcitonin, by Type USD Million (2025-2030)
  • Table 193. Canada Procalcitonin, by Application USD Million (2025-2030)
  • Table 194. Canada Procalcitonin, by End use USD Million (2025-2030)
  • Table 195. Mexico Procalcitonin, by Type USD Million (2025-2030)
  • Table 196. Mexico Procalcitonin, by Application USD Million (2025-2030)
  • Table 197. Mexico Procalcitonin, by End use USD Million (2025-2030)
  • Table 198. Procalcitonin: by Type(USD/Units)
  • Table 199. Research Programs/Design for This Report
  • Table 200. Key Data Information from Secondary Sources
  • Table 201. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Procalcitonin: by Type USD Million (2018-2023)
  • Figure 5. Global Procalcitonin: by Application USD Million (2018-2023)
  • Figure 6. Global Procalcitonin: by End use USD Million (2018-2023)
  • Figure 7. South America Procalcitonin Share (%), by Country
  • Figure 8. Asia Pacific Procalcitonin Share (%), by Country
  • Figure 9. Europe Procalcitonin Share (%), by Country
  • Figure 10. MEA Procalcitonin Share (%), by Country
  • Figure 11. North America Procalcitonin Share (%), by Country
  • Figure 12. Global Procalcitonin: by Type USD/Units (2018-2023)
  • Figure 13. Global Procalcitonin share by Players 2023 (%)
  • Figure 14. Global Procalcitonin share by Players (Top 3) 2023(%)
  • Figure 15. Global Procalcitonin share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Thermo Fisher (United States) Revenue, Net Income and Gross profit
  • Figure 18. Thermo Fisher (United States) Revenue: by Geography 2023
  • Figure 19. Roche Diagnostics (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. Roche Diagnostics (Switzerland) Revenue: by Geography 2023
  • Figure 21. BioMerieux (France) Revenue, Net Income and Gross profit
  • Figure 22. BioMerieux (France) Revenue: by Geography 2023
  • Figure 23. HyTest (Finland) Revenue, Net Income and Gross profit
  • Figure 24. HyTest (Finland) Revenue: by Geography 2023
  • Figure 25. BBI Solutions (Brazil) Revenue, Net Income and Gross profit
  • Figure 26. BBI Solutions (Brazil) Revenue: by Geography 2023
  • Figure 27. ProSpec (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. ProSpec (United Kingdom) Revenue: by Geography 2023
  • Figure 29. CPN (Thailand) Revenue, Net Income and Gross profit
  • Figure 30. CPN (Thailand) Revenue: by Geography 2023
  • Figure 31. Kewpie (Japan) Revenue, Net Income and Gross profit
  • Figure 32. Kewpie (Japan) Revenue: by Geography 2023
  • Figure 33. Shiseido (Japan) Revenue, Net Income and Gross profit
  • Figure 34. Shiseido (Japan) Revenue: by Geography 2023
  • Figure 35. Novozymes (Denmark) Revenue, Net Income and Gross profit
  • Figure 36. Novozymes (Denmark) Revenue: by Geography 2023
  • Figure 37. Global Procalcitonin: by Type USD Million (2025-2030)
  • Figure 38. Global Procalcitonin: by Application USD Million (2025-2030)
  • Figure 39. Global Procalcitonin: by End use USD Million (2025-2030)
  • Figure 40. South America Procalcitonin Share (%), by Country
  • Figure 41. Asia Pacific Procalcitonin Share (%), by Country
  • Figure 42. Europe Procalcitonin Share (%), by Country
  • Figure 43. MEA Procalcitonin Share (%), by Country
  • Figure 44. North America Procalcitonin Share (%), by Country
  • Figure 45. Global Procalcitonin: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Thermo Fisher (United States)
  • Roche Diagnostics (Switzerland)
  • BioMerieux (France)
  • HyTest (Finland)
  • BBI Solutions (Brazil)
  • ProSpec (United Kingdom)
  • CPN (Thailand)
  • Kewpie (Japan)
  • Shiseido (Japan)
  • Novozymes (Denmark)
Additional players considered in the study are as follows:
Bloomage BioTechnology (China) , Shandong Galaxy Bio-Tech (China) , Shandong Focuschem Biotech Co., Ltd. (China) , Shandong Topscience Biotech (China) , QuFu GuangLong Biochem (China)
Select User Access Type

Key Highlights of Report


Apr 2024 209 Pages 50 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Procalcitonin Quantitative research analysis
Global Procalcitonin Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Procalcitonin Market are by type [Polyclonal Procalcitonin Antibody and Monoclonal Procalcitonin Antibody], by end use application [Diagnose Sepis, Diagnose Kidney Infections and Monitor the Effectivenees of Antibiotics Therapy].
The Procalcitonin Market is gaining popularity and expected to see strong valuation by 2030.
  • Rising Bacterial Infections and Diseases Among the People
  • Usage in Diagnosis of Various Infections Such as Kidney

Know More About Global Procalcitonin Report?

Have a Query? Click Here

Other Related Reports

Speech Therapy Services Comprehensive Study by Treatment (Articulation Therapy, Language Intervention Therapy, Oral Motor Therapy, VitalStim Therapy, LSVT (Lee Silverman Speech Therapy)), Indication ...
$ 3500
Radiation Dose Management Comprehensive Study by Type (Software, Services, Consulting Services, Others), Application (Hospitals and Clinics, Diagnostic Centers, Research Centers and Academic Medical ...
$ 3750
Pharmacovigilance Comprehensive Study by End User (Hospitals, Research Organizations, Others), Service Provider (In-house, Contract Outsourcing), Pharmacovigilance Methods (Spontaneous Reporting,...
$ 3450
Digital Fitness Comprehensive Study by Type (Hand Wear, Leg Wear, Head Wear, Others), Application (Commercial, Household), Device types (Smartwatch, Wristband, Smart Clothing, Smart Shoes, Bike Compu...
$ 3800
Laser Therapy Caps Comprehensive Study by Type (Caps, Helmets), Application (Hair Loss Treatment, Hair Regrowth), Distribution Channel (Pharmacy Stores, E-commerce, Others) Players and Region - Globa...
$ 3500
Animal Health Care Comprehensive Study by Type (Companion Animals, Farm Animals), Application (Veterinary Hospitals, Veterinary Clinics, Pharmacies & Drug Stores, Online Pharmacies), Distribution Cha...
$ 3450